Form 4: Avidity Biosciences CEO Acquires Stock and Options in Recent Transaction
SEC Form 4 Filing
Avidity Biosciences CEO, Sarah Boyce, acquired 82,500 shares of restricted stock units and 165,000 stock options on January 6, 2025.
Summary
- Avidity Biosciences CEO, Sarah Boyce, has reported a transaction involving the acquisition of company stock and options.
- On January 6, 2025, Ms. Boyce acquired 82,500 restricted stock units (RSUs), which will vest in four equal installments annually starting January 6, 2026.
- She also acquired 165,000 stock options with an exercise price of $31.42, vesting monthly over four years until January 6, 2029.
- Following these transactions, Ms. Boyce directly owns 347,808 shares of common stock and 165,000 stock options.
Sentiment
Score: 7
Explanation: The document reflects a positive sentiment as it shows the CEO's increased stake in the company, which is generally viewed favorably by investors. The vesting schedules also indicate a long-term commitment.
Positives
- The acquisition of stock and options by the CEO demonstrates confidence in the company's future performance.
- The vesting schedules for both the RSUs and options align with long-term value creation for the company.
Industry Context
This type of transaction is common for executives in publicly traded companies as part of their compensation and incentive packages.
Comparison to Industry Standards
- Stock option and RSU grants are standard practice for executive compensation in the biotechnology industry.
- Vesting schedules are typically structured to incentivize long-term performance and retention, similar to other companies in the sector such as Alnylam Pharmaceuticals and Ionis Pharmaceuticals.
Stakeholder Impact
- The transaction may positively impact shareholder confidence due to the CEO's increased stake in the company.
- Employees may view this as a positive sign of the company's future prospects.
Key Dates
| Date | Description |
|---|---|
| 01/06/2025 | Date of the transaction where the CEO acquired RSUs and stock options. |
| 01/06/2026 | First vesting date for the restricted stock units. |
| 01/06/2029 | Final vesting date for the stock options. |
| 01/05/2035 | Expiration date for the stock options. |
| 01/08/2025 | Date the form was signed by the Attorney-in-Fact. |
Keywords
Avidity Biosciences, Sarah Boyce, stock options, restricted stock units, insider trading, executive compensation, RNA
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.